Selected research
Industry Research
Hepatitis A Inactivated Vaccine Industry Research Report 2026
Market perspective
The global Hepatitis A Inactivated Vaccine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Hepatitis A Inactivated Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Hepatitis A Inactivated Vaccine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Hepatitis A Inactivated Vaccine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Hepatitis A Inactivated Vaccine include Xianghe Pharmaceutical, Sanofi, Merck, Pfizer, GlaxoSmithKline, Limin Pharmaceutical, Huakang Pharmaceutical and Health Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Hepatitis A Inactivated Vaccine market in terms of revenue (US$ million) and, where applicable, sales volume (L), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/L) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Hepatitis A Inactivated Vaccine Market by Company
Xianghe Pharmaceutical
Sanofi
Merck
Pfizer
GlaxoSmithKline
Limin Pharmaceutical
Huakang Pharmaceutical
Health Pharma
Hepatitis A Inactivated Vaccine Segment by Type
25U/0.5ml
50U/1.0ml
Hepatitis A Inactivated Vaccine Segment by Application
Hospital
Clinic
Others
Hepatitis A Inactivated Vaccine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hepatitis A Inactivated Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hepatitis A Inactivated Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hepatitis A Inactivated Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Hepatitis A Inactivated Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Hepatitis A Inactivated Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Hepatitis A Inactivated Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 25U/0.5ml
- 50U/1.0ml
Applications
- Hospital
- Clinic
- Others
Companies covered
- Xianghe Pharmaceutical
- Sanofi
- Merck
- Pfizer
- GlaxoSmithKline
- Limin Pharmaceutical
- Huakang Pharmaceutical
- Health Pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Hepatitis A Inactivated Vaccine Market Size (2021-2032)
- 2.2.2 Global Hepatitis A Inactivated Vaccine Sales (2021-2032)
- 2.2.3 Global Hepatitis A Inactivated Vaccine Market Average Price (2021-2032)
- 2.3 Hepatitis A Inactivated Vaccine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 25U/0.5ml
- 2.3.3 50U/1.0ml
- 2.4 Hepatitis A Inactivated Vaccine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Hepatitis A Inactivated Vaccine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Hepatitis A Inactivated Vaccine Sales (L) of Manufacturers (2021-2026)
- 3.3 Global Hepatitis A Inactivated Vaccine Revenue of Manufacturers (2021-2026)
- 3.4 Global Hepatitis A Inactivated Vaccine Average Price by Manufacturers (2021-2026)
- 3.5 Global Hepatitis A Inactivated Vaccine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Hepatitis A Inactivated Vaccine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Hepatitis A Inactivated Vaccine, Product Type & Application
- 3.8 Global Manufacturers of Hepatitis A Inactivated Vaccine, Established Date
- 3.9 Global Hepatitis A Inactivated Vaccine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Xianghe Pharmaceutical
- 4.1.1 Xianghe Pharmaceutical Company Information
- 4.1.2 Xianghe Pharmaceutical Business Overview
- 4.1.3 Xianghe Pharmaceutical Hepatitis A Inactivated Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Xianghe Pharmaceutical Hepatitis A Inactivated Vaccine Product Portfolio
- 4.1.5 Xianghe Pharmaceutical Recent Developments
- 4.2 Sanofi
- 4.2.1 Sanofi Company Information
- 4.2.2 Sanofi Business Overview
- 4.2.3 Sanofi Hepatitis A Inactivated Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Sanofi Hepatitis A Inactivated Vaccine Product Portfolio
- 4.2.5 Sanofi Recent Developments
- 4.3 Merck
- 4.3.1 Merck Company Information
- 4.3.2 Merck Business Overview
- 4.3.3 Merck Hepatitis A Inactivated Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Merck Hepatitis A Inactivated Vaccine Product Portfolio
- 4.3.5 Merck Recent Developments
- 4.4 Pfizer
- 4.4.1 Pfizer Company Information
- 4.4.2 Pfizer Business Overview
- 4.4.3 Pfizer Hepatitis A Inactivated Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Pfizer Hepatitis A Inactivated Vaccine Product Portfolio
- 4.4.5 Pfizer Recent Developments
- 4.5 GlaxoSmithKline
- 4.5.1 GlaxoSmithKline Company Information
- 4.5.2 GlaxoSmithKline Business Overview
- 4.5.3 GlaxoSmithKline Hepatitis A Inactivated Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 GlaxoSmithKline Hepatitis A Inactivated Vaccine Product Portfolio
- 4.5.5 GlaxoSmithKline Recent Developments
- 4.6 Limin Pharmaceutical
- 4.6.1 Limin Pharmaceutical Company Information
- 4.6.2 Limin Pharmaceutical Business Overview
- 4.6.3 Limin Pharmaceutical Hepatitis A Inactivated Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Limin Pharmaceutical Hepatitis A Inactivated Vaccine Product Portfolio
- 4.6.5 Limin Pharmaceutical Recent Developments
- 4.7 Huakang Pharmaceutical
- 4.7.1 Huakang Pharmaceutical Company Information
- 4.7.2 Huakang Pharmaceutical Business Overview
- 4.7.3 Huakang Pharmaceutical Hepatitis A Inactivated Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Huakang Pharmaceutical Hepatitis A Inactivated Vaccine Product Portfolio
- 4.7.5 Huakang Pharmaceutical Recent Developments
- 4.8 Health Pharma
- 4.8.1 Health Pharma Company Information
- 4.8.2 Health Pharma Business Overview
- 4.8.3 Health Pharma Hepatitis A Inactivated Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Health Pharma Hepatitis A Inactivated Vaccine Product Portfolio
- 4.8.5 Health Pharma Recent Developments
5 Global Hepatitis A Inactivated Vaccine Market Scenario by Region
- 5.1 Global Hepatitis A Inactivated Vaccine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Hepatitis A Inactivated Vaccine Sales by Region: 2021-2032
- 5.2.1 Global Hepatitis A Inactivated Vaccine Sales by Region: 2021-2026
- 5.2.2 Global Hepatitis A Inactivated Vaccine Sales by Region: 2027-2032
- 5.3 Global Hepatitis A Inactivated Vaccine Revenue by Region: 2021-2032
- 5.3.1 Global Hepatitis A Inactivated Vaccine Revenue by Region: 2021-2026
- 5.3.2 Global Hepatitis A Inactivated Vaccine Revenue by Region: 2027-2032
- 5.4 North America Hepatitis A Inactivated Vaccine Market Facts & Figures by Country
- 5.4.1 North America Hepatitis A Inactivated Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Hepatitis A Inactivated Vaccine Sales by Country (2021-2032)
- 5.4.3 North America Hepatitis A Inactivated Vaccine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Hepatitis A Inactivated Vaccine Market Facts & Figures by Country
- 5.5.1 Europe Hepatitis A Inactivated Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Hepatitis A Inactivated Vaccine Sales by Country (2021-2032)
- 5.5.3 Europe Hepatitis A Inactivated Vaccine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Hepatitis A Inactivated Vaccine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Hepatitis A Inactivated Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Hepatitis A Inactivated Vaccine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Hepatitis A Inactivated Vaccine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Hepatitis A Inactivated Vaccine Market Facts & Figures by Country
- 5.7.1 South America Hepatitis A Inactivated Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Hepatitis A Inactivated Vaccine Sales by Country (2021-2032)
- 5.7.3 South America Hepatitis A Inactivated Vaccine Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Hepatitis A Inactivated Vaccine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Hepatitis A Inactivated Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Hepatitis A Inactivated Vaccine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Hepatitis A Inactivated Vaccine Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Hepatitis A Inactivated Vaccine Sales by Type (2021-2032)
- 6.1.1 Global Hepatitis A Inactivated Vaccine Sales by Type (2021-2032) & (L)
- 6.1.2 Global Hepatitis A Inactivated Vaccine Sales Market Share by Type (2021-2032)
- 6.2 Global Hepatitis A Inactivated Vaccine Revenue by Type (2021-2032)
- 6.2.1 Global Hepatitis A Inactivated Vaccine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Hepatitis A Inactivated Vaccine Revenue Market Share by Type (2021-2032)
- 6.3 Global Hepatitis A Inactivated Vaccine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Hepatitis A Inactivated Vaccine Sales by Application (2021-2032)
- 7.1.1 Global Hepatitis A Inactivated Vaccine Sales by Application (2021-2032) & (L)
- 7.1.2 Global Hepatitis A Inactivated Vaccine Sales Market Share by Application (2021-2032)
- 7.2 Global Hepatitis A Inactivated Vaccine Revenue by Application (2021-2032)
- 7.2.1 Global Hepatitis A Inactivated Vaccine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Hepatitis A Inactivated Vaccine Revenue Market Share by Application (2021-2032)
- 7.3 Global Hepatitis A Inactivated Vaccine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Hepatitis A Inactivated Vaccine Value Chain Analysis
- 8.1.1 Hepatitis A Inactivated Vaccine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Hepatitis A Inactivated Vaccine Production Mode & Process
- 8.2 Hepatitis A Inactivated Vaccine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Hepatitis A Inactivated Vaccine Distributors
- 8.2.3 Hepatitis A Inactivated Vaccine Customers
9 Global Hepatitis A Inactivated Vaccine Analyzing Market Dynamics
- 9.1 Hepatitis A Inactivated Vaccine Industry Trends
- 9.2 Hepatitis A Inactivated Vaccine Industry Drivers
- 9.3 Hepatitis A Inactivated Vaccine Industry Opportunities and Challenges
- 9.4 Hepatitis A Inactivated Vaccine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst